Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Eli Lilly and Company
Eli Lilly and Company
Alliance Foundation Trials, LLC.
Northwestern University
Takeda
Brown University
ImmunityBio, Inc.
M.D. Anderson Cancer Center
ImmunityBio, Inc.
AstraZeneca
The Lymphoma Academic Research Organisation
Northwestern University
Indiana University
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
Sun Yat-sen University
University of Washington
M.D. Anderson Cancer Center
Ruijin Hospital
Brown University
Miltenyi Biomedicine GmbH
University of Rochester
Washington University School of Medicine
University of Utah
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Celgene
Fred Hutchinson Cancer Center
University of Washington
Regeneron Pharmaceuticals
City of Hope Medical Center
M.D. Anderson Cancer Center
Hospices Civils de Lyon
Mayo Clinic
Shanghai Junshi Bioscience Co., Ltd.
Wake Forest University Health Sciences
Chinese PLA General Hospital
Roswell Park Cancer Institute
University of Maryland, Baltimore
University of Chicago
CARGO Therapeutics
Columbia University
Miltenyi Biomedicine GmbH